NCT02709109View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

PHASE2CompletedINTERVENTIONAL

Enrollment

147

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-371 + HS

DRUG

Hypertonic saline

DRUG

Placebo

DRUG

Orkambi

DRUG

VX-371

Trial Locations (40)

Unknown

Little Rock

Oakland

Gainesville

Miami

Orlando

Chicago

Glenview

Kansas City

New Orleans

Worcester

Detroit

Grand Rapids

Minneapolis

Jackson

Lebanon

Albuquerque

Albany

Hawthorne

Syracuse

Charlotte

Cleveland

Pittsburgh

Austin

Dallas

Fort Worth

Tyler

Charlottesville

Richmond

Madison

Milwaukee

Bron

Pierre-Bénite

Roscoff

Strasbourg

Dublin

Birmingham

Bristol

London

Manchester

Southampton

Sponsors

Lead Sponsor

Parion Sciences

All Listed Sponsors

collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Parion Sciences

INDUSTRY